Product Information
BORTEZOMIB 3.5 MG VIAL is a generic product labeled by Zydus Pharmaceuticals (USA) Inc., priced at $43.3460 per EA under NDC 70710141101. Its NADAC has been published 48 times since May 22, 2024.
FDA first approved this application on May 2, 2022. Its Orange Book therapeutic-equivalence code is AP.
Strength
1 mg/mL
Manufacturer
Zydus Pharmaceuticals (USA) Inc.NDC
70710141101
Classification
Generic
Dosage Form
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Route
INTRAVENOUS; SUBCUTANEOUS
Effective Date
3/19/2025
Active Ingredients
BORTEZOMIBApproval Type
Generic (ANDA)
FDA Application
ANDA210204FDA Approved
5/2/2022
TE Code
AP
On Market Since
5/2/2022
Pharmacological Classes
Price Statistics
The NADAC for BORTEZOMIB 3.5 MG VIAL has been published 48 times since May 22, 2024, and over the history we have for it it has risen 46.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $43.3460 per EA |
|---|---|
| All-time high | $43.3460 (Apr 16, 2025) |
| All-time low | $29.6580 (May 22, 2024) |
| Median price | $34.7100 |
| Average price | $36.5803 |
| Largest weekly change | +24.9% (Dec 18, 2024) |
| Weeks tracked | 48 |
| Tracking since | May 22, 2024 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
+46.2%
Last surveyed Apr 16, 2025 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the BORTEZOMIB market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Zydus Pharmaceuticals (USA) Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
BORTEZOMIB market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Proteasome Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BORTEZOMIB 3.5 MG VIAL?
The current National Average Drug Acquisition Cost (NADAC) for BORTEZOMIB 3.5 MG VIAL, manufactured by Zydus Pharmaceuticals (USA) Inc., is $43.3460 per EA (NDC 70710141101), effective Apr 16, 2025.
How has the price of BORTEZOMIB 3.5 MG VIAL changed over time?
Over the history we have for it, the NADAC for BORTEZOMIB 3.5 MG VIAL has risen 46.2%. It has been tracked across 48 weekly CMS publications since May 22, 2024.
What are the highest and lowest recorded NADAC prices for BORTEZOMIB 3.5 MG VIAL?
Since May 22, 2024, the NADAC for BORTEZOMIB 3.5 MG VIAL has ranged from a low of $29.6580 (May 22, 2024) to a high of $43.3460 (Apr 16, 2025), with a median of $34.7100 per EA.
Are there cheaper alternatives to BORTEZOMIB 3.5 MG VIAL?
No other NADAC-published product currently shares the active ingredient and strength of BORTEZOMIB 3.5 MG VIAL in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures BORTEZOMIB 3.5 MG VIAL?
BORTEZOMIB 3.5 MG VIAL (NDC 70710141101) is labeled by Zydus Pharmaceuticals (USA) Inc., and CMS classifies it as a generic product.